Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (ACRX) on March 30, 2023. The filing serves to announce financial results for the three and twelve months ended December 31, 2022, and to disclose a material error in previously issued interim financial statements.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing specific revenue, profit, and cash flow data for the periods ended December 31, 2022, but the text of this 8-K does not provide specific numerical values for these metrics. The filing explicitly states that the identified accounting error has no impact on the Company's cash balance, liquidity, revenues, operating expenses, or total net income.
Material Changes and Restatements
The Company identified an error in the earnings per share (EPS) calculations for the interim periods ended June 30, 2022, and September 30, 2022. The error resulted from the failure to properly apply the two-class method of calculating EPS regarding warrants issued in November 2021, which are participating securities. Consequently, management and the Audit Committee determined that the prior interim financial statements should no longer be relied upon and will be restated in the upcoming Form 10-K for the year ended December 31, 2022. Financial statements for the year ended December 31, 2021, and the quarter ended March 31, 2022, were not impacted.
Outlook, Risks, and Management Commentary
Management confirmed that the EPS calculation error does not affect the Company's balance sheet accounts or cash flows. The filing notes that the information contained in the press release is "furnished" and not "filed" for purposes of liability under the Securities Exchange Act of 1934. No specific forward-looking guidance or new risk factors were detailed in the text of this 8-K beyond the restatement notice.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the March 30, 2023, press release (Exhibit 99.1) referenced in this filing.
- Monitor the upcoming Form 10-K for the year ended December 31, 2022, to review the restated EPS figures for the interim periods of 2022.
- Confirm that the restatement is limited to EPS calculations and does not alter total net income or cash flow positions.
- Review the details of the November 2021 warrant issuance to understand the participating securities classification.